Overview
Nuvation Bio beat analysts' expectations for Q3 revenue, driven by IBTROZI sales
Company reported Q3 net loss of $55.8 mln
204 patients started on IBTROZI in Q3, indicating strong launch progress
Outlook
Company expects $25 mln milestone payment from Nippon Kayaku by year-end
Nuvation Bio plans sNDA to update IBTROZI label with recent data
Company expects taletrectinib listing on China's National Reimbursement Drug List in 2026
Result Drivers
IBTROZI LAUNCH - 204 patients started treatment with IBTROZI in Q3, reflecting strong launch progress
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $13.12 mln | $6.61 mln (7 Analysts) |
Q3 EPS | -$0.16 | ||
Q3 Net Income | -$55.79 mln | ||
Q3 Income from Pperations | -$56.43 mln | ||
Q3 Operating Expenses | $66.20 mln | ||
Q3 Pretax Profit | -$55.79 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Nuvation Bio Inc is $10.00, about 47.8% above its October 31 closing price of $5.22
Press Release: ID:nBw3hfs1Za
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)